Read Why HTG Molecular Shares Are Surging Today

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) says it has improved the sample preparation protocol for its miRNA Whole Transcriptome Assay (miRNA WTA) to be harmonized with the HTG Transcriptome Panel (HTP).
The harmonized protocol enables customers to process a single sample with HTG's nearly 20,000 gene mRNA and 2,000+ miRNA transcriptome panels using a single sample lysate.
Validated for use with several commonly used sample types, this approach allows customers to save time with better sample and workflow efficiency while generating more comprehensive expression data.
"We believe HTG now offers the only solution enabling extraction-free full transcriptomic profiling, both mRNA and miRNA, from a single tissue section," said Byron Lawson, HTG's Senior Vice President and Chief Commercial Officer.
"Alternate GEP technologies typically require a minimum of 4-8 tissue sections, and often 12 or more sections for RNA extraction and separate library preparation methods for RNA size selection for mRNA and miRNA processing. Our technology offers customers a streamlined workflow, with more efficient turnaround times and simplified bioinformatics," Lawson added.
Price Action: HTGM shares are up 31.30% at $1.68 during the premarket session on the last check Thursday.